Disopyramide phosphate market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to boost the market during the forecast period include an increase in the prevalence of arrhythmias and ventricular tachycardia among patients with heart problems, rise in R&D activities to develop advanced products, and significant rise in the geriatric population. However, side effects associated with drugs and stringent government regulations towards the approval of disopyramide phosphate drugs restrict the market growth. An increase in clinical trials and development of drugs with better efficacy and lesser side effects are expected to provide a number of opportunities for pharmaceutical industries, thereby fuelling the growth of the market during the forecast period.
Disopyramide is an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has an anticholinergic effect on the heart which accounts for many adverse side effects. Disopyramide is available in both oral and intravenous forms, and has a low degree of toxicity. Disopyramide phosphate is a class I anti-arrhythmic drug used to treat cardiac arrhythmias. It interferes with the depolarization of the cardiac membrane that results in depressant action on the heart rhythm. The drug is used to treat arrhythmias and prevent paroxysmal supraventricular tachycardia. Disopyramide, despite its efficacy, has one main side effect that has limited its use in the US, though it has seen wider application in Canada, UK and Japan, which is a factor that will propel the market during the forecast period. The global disopyramide phosphate market is segmented on the basis of brand, patient type, and region. Based on drug brand, it is divided into Norpace and Rythmodan. According to patient type, it is segmented into infants, children, adolescents, and geriatric. Geographically, the market is segmented into North America, Europe, Asia-Pacific, and Latin America and Middle-East and Africa.
To Request a Sample of our Report on DIsopyramide Phosphate Market: https://www.omrglobal.com/request-sample/dIsopyramide-phosphate-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Drug Brand
- By Patient Type
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Sanofi S.A., Merck KGaA, and Pfizer Inc., among others.
Disopyramide Phosphate Market Report by Segment
By Drug Brand
- Norpace
- Rythmodan
By Patient Type
- Infants
- Children
- Adolescents
- Geriatric
A full Report of DIsopyramide Phosphate Market is Available @ https://www.omrglobal.com/industry-reports/dIsopyramide-phosphate-market
Disopyramide Phosphate Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
